Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Cirrhosis
  Free Subscription

Articles published in
Gut
    February 2026
  1. CHEN Y, Dong B, Jin X, Liu C, et al
    Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes.
    Gut. 2026;75:576-587.
    >> Share

  2. ROMEO M, Dallio M, Di Nardo F, Napolitano C, et al
    Beyond gastrointestinal symptom burden: exploring the impact of previous cholecystectomy on ultrasound-based hepatocellular carcinoma surveillance in patients with liver cirrhosis.
    Gut. 2026 Feb 3:gutjnl-2026-338023. doi: 10.1136/gutjnl-2026-338023.
    >> Share

    January 2026
  3. DE SCHEPPER S, Wiest R
    When the vascular lining loosens, dysfunctional macrophages permit pathological bacterial translocation in cirrhosis.
    Gut. 2026 Jan 2:gutjnl-2025-337412. doi: 10.1136/gutjnl-2025-337412.
    >> Share

    November 2025
  4. SMETS L, Viola MF, Boesch M, Raman J, et al
    Intestinal blood vessel-associated macrophages and gut-vascular barrier dysfunction in cirrhosis.
    Gut. 2025 Nov 18:gutjnl-2025-335745. doi: 10.1136/gutjnl-2025-335745.
    >> Share

    September 2025
  5. FENG G, Wong VW, Targher G, Byrne CD, et al
    Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring.
    Gut. 2025;74:1741-1750.
    >> Share

    August 2025

  6. Correction: Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis.
    Gut. 2025;74:e18.
    >> Share

    June 2025
  7. NIU J, Gao Y, Wang G, Qin Z, et al
    Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trial.
    Gut. 2025 Jun 24:gutjnl-2025-335577. doi: 10.1136/gutjnl-2025-335577.
    >> Share

  8. LAI JC, Yang B, Lee HW, Lin H, et al
    Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease.
    Gut. 2025 Jun 20:gutjnl-2025-334981. doi: 10.1136/gutjnl-2025-334981.
    >> Share

  9. CHEN J, Xu X, Yang S, Yu X, et al
    Validation of the CLIF-SIG score in patients with HBV-related acutely decompensated cirrhosis.
    Gut. 2025 Jun 19:gutjnl-2025-335810. doi: 10.1136/gutjnl-2025-335810.
    >> Share

    April 2025
  10. PINTER M, Fulgenzi CAM, Pinato DJ, Scheiner B, et al
    Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction.
    Gut. 2025 Apr 29:gutjnl-2025-334928. doi: 10.1136/gutjnl-2025-334928.
    >> Share

    February 2025
  11. TREBICKA J, Aguilar F, Queiroz Farias A, Lozano JJ, et al
    Gene score to quantify systemic inflammation in patients with acutely decompensated cirrhosis.
    Gut. 2025 Feb 26:gutjnl-2024-333876. doi: 10.1136/gutjnl-2024-333876.
    >> Share

    November 2024
  12. MAO X, Zhang X, Kam L, Chien N, et al
    Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.
    Gut. 2024;73:2054-2061.
    >> Share

  13. SINGAL AG, Narasimman M, Daher D, Yekkaluri S, et al
    Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomised clinical trial.
    Gut. 2024;73:2037-2044.
    >> Share

    October 2024
  14. VAN DER MERWE SW, G Fernandez-Barrena M
    Safe and successful gut-restricted adsorbent strategy against cirrhosis and acute-on-chronic liver failure.
    Gut. 2024 Oct 26:gutjnl-2024-332457. doi: 10.1136/gutjnl-2024-332457.
    >> Share

  15. LINK F, Li Y, Zhao J, Munker S, et al
    ECM1 attenuates hepatic fibrosis by interfering with mediators of latent TGF-beta1 activation.
    Gut. 2024 Oct 24:gutjnl-2024-333213. doi: 10.1136/gutjnl-2024-333213.
    >> Share


  16. Correction: Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation.
    Gut. 2024;73:e32.
    >> Share

  17. SHANG Y, Akbari C, Dodd M, Nasr P, et al
    Cause of death by fibrosis stage in 959 patients with biopsy-proven NAFLD.
    Gut. 2024;73:e30.
    >> Share

    September 2024
  18. ZIPPRICH A, Hernaez R
    High-risk varices in patients with Child-Pugh-Turcotte B and C: consider band ligation with carvedilol for preventing first variceal bleeding, especially in patients with MASLD-associated cirrhosis.
    Gut. 2024 Sep 18:gutjnl-2024-333263. doi: 10.1136/gutjnl-2024-333263.
    >> Share

    August 2024
  19. YANG AH, Tincopa MA, Tavaglione F, Ajmera VH, et al
    Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA.
    Gut. 2024 Aug 7:gutjnl-2024-332917. doi: 10.1136/gutjnl-2024-332917.
    >> Share

    July 2024
  20. TEVETHIA HV, Pande A, Vijayaraghavan R, Kumar G, et al
    Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'.
    Gut. 2024 Jul 27:gutjnl-2023-331181. doi: 10.1136/gutjnl-2023-331181.
    >> Share

    May 2024
  21. BABUTA M, Morel C, de Carvalho Ribeiro M, Calenda C, et al
    Neutrophil extracellular traps activate hepatic stellate cells and monocytes via NLRP3 sensing in alcohol-induced acceleration of MASH fibrosis.
    Gut. 2024 May 22:gutjnl-2023-331447. doi: 10.1136/gutjnl-2023-331447.
    >> Share

    April 2024
  22. BREITKOPF-HEINLEIN K, Martinez-Chantar ML
    Targeting hepatic stellate cells to combat liver fibrosis: where do we stand?
    Gut. 2024 Apr 25:gutjnl-2023-331785. doi: 10.1136/gutjnl-2023-331785.
    >> Share

  23. LIU J, MacNaughtan J, Kerbert AJC, Portlock T, et al
    Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis.
    Gut. 2024 Apr 15:gutjnl-2023-330699. doi: 10.1136/gutjnl-2023-330699.
    >> Share

  24. ARMANDI A, Sanavia T, Younes R, Caviglia GP, et al
    Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease.
    Gut. 2024;73:825-834.
    >> Share

    March 2024
  25. TREBICKA J, Hernaez R, Shawcross DL, Gerbes AL, et al
    Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers.
    Gut. 2024 Mar 25:gutjnl-2023-330584. doi: 10.1136/gutjnl-2023-330584.
    >> Share

    February 2024
  26. EL-SERAG H, Kanwal F, Ning J, Powell H, et al
    Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis.
    Gut. 2024 Feb 16:gutjnl-2024-332034. doi: 10.1136/gutjnl-2024-332034.
    >> Share

    January 2024

  27. Correction: P23 Opportunistic cirrhosis case finding in alcohol dependent inpatients through alcohol specialist nurse assessment and transient elastography: early detection in a high-risk group.
    Gut. 2024;73:e3.
    >> Share

  28. KONG M, Zhou J, Kang A, Kuai Y, et al
    Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis.
    Gut. 2024 Jan 4:gutjnl-2023-329671. doi: 10.1136/gutjnl-2023-329671.
    >> Share

    December 2023
  29. CHOUIK Y, Levrero M
    Monocyte phenotypic liquid biopsy for NASH and liver fibrosis diagnosis: a new kid on the block.
    Gut. 2023;73:10-11.
    >> Share

    November 2023
  30. ZHANG X, Yip TC, Wong GL, Leow WX, et al
    Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial.
    Gut. 2023;72:2364-2371.
    >> Share


  31. Correction: Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
    Gut. 2023;72:e4.
    >> Share

    October 2023
  32. JUANOLA A, Ma AT, de Wit K, Gananandan K, et al
    Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.
    Gut. 2023 Oct 26:gutjnl-2023-329923. doi: 10.1136/gutjnl-2023-329923.
    >> Share

  33. CHOI WM, Kim GA, Choi J, Choi GH, et al
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Gut. 2023 Oct 9:gutjnl-2023-330225. doi: 10.1136/gutjnl-2023-330225.
    >> Share

  34. CIOCAN D, Turpin W
    New insights into an old paradigm: why IgA accumulates in alcoholic liver disease and what could be its role.
    Gut. 2023;72:1812-1814.
    >> Share

    September 2023
  35. MANTOVANI A, Tilg H, Targher G
    FGF-21 analogues for treatment of non-alcoholic steatohepatitis and fibrosis: a meta-analysis with fragility index of phase 2 randomised placebo-controlled trials.
    Gut. 2023 Sep 27:gutjnl-2023-331115. doi: 10.1136/gutjnl-2023-331115.
    >> Share

    July 2023
  36. ZHAO L, Wu Q, Li Q, Chen A, et al
    TIPSS plus extrahepatic collateral embolisation may decrease variceal rebleeding and post-TIPSS hepatic encephalopathy.
    Gut. 2023 Jul 31:gutjnl-2023-330255. doi: 10.1136/gutjnl-2023-330255.
    >> Share

  37. HE X, Gao N, Lv F, Wu F, et al
    Temporal trend of mortality in patients with cirrhosis with primary biliary cholangitis and primary sclerosing cholangitis during the COVID-19 pandemic.
    Gut. 2023 Jul 24:gutjnl-2023-330271. doi: 10.1136/gutjnl-2023-330271.
    >> Share

  38. MANTOVANI A, Csermely A, Tilg H, Byrne CD, et al
    Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals.
    Gut. 2023;72:1433-1436.
    >> Share

    June 2023
  39. WITTKOP L, Boettler T
    More than shots in the dark: driving vaccine efficacy in cirrhosis.
    Gut. 2023 Jun 7:gutjnl-2023-329867. doi: 10.1136/gutjnl-2023-329867.
    >> Share

    March 2023
  40. GIRALDEZ-GALLEGO A, Rodriguez-Seguel EDP, Valencia-Martin R, Morillo-Garcia A, et al
    Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: an open-label randomised clinical trial.
    Gut. 2023 Mar 24:gutjnl-2022-328222. doi: 10.1136/gutjnl-2022-328222.
    >> Share

    January 2023
  41. RAVAIOLI F, Dajti E, Mantovani A, Newsome PN, et al
    Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis.
    Gut. 2023 Jan 4:gutjnl-2022-328689. doi: 10.1136/gutjnl-2022-328689.
    >> Share

    June 2022
  42. AWONIYI M, Wang J, Ngo B, Meadows V, et al
    Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC.
    Gut. 2022 Jun 15. pii: gutjnl-2021-326500. doi: 10.1136/gutjnl-2021-326500.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016